Biopharmaceuticals Panel

 
 

“Enhancing R&D Productivity and Value Proposition to Payers”

SAMPLE ISSUES

  • How companies are enhancing R&D productivity in a resource constrained environment.
  • Examples of risk mitigation strategies employed at various stages of a compound's development and commercialization path, including partnering strategies.
  • Effective strategies to enhance the value proposition to payers (clinical, economic).
  • Biomarkers/companion diagnostics - targets, regulatory framework (US/EU), integration in clinical development, own vs. partner, payer response, etc.
  • Prospects for biosimiliars - what to expect (regulator, targets, timing, players, ROI, etc.).
  • Emerging markets strategies and profit potential - near-term and longer-term?
  • Financing options for early-stage biopharma companies, and funding trategies for acquisitions in the sector.

Cliff Cramer
Adjunct Professor and Director, Healthcare and Pharmaceutical Management Program
Columbia Business School

Cliff Cramer spent over 25 years as a senior professional in the financial services and healthcare/ pharmaceutical sectors. He was Managing Director at JP Morgan and Merrill Lynch in their global healthcare investment banking groups, and Vice President, Corporate Planning & Development at Merck & Co., Inc., with worldwide responsibilities for strategic planning and business development.

Mr. Cramer’s previous experience includes the co-founding of American Health Capital / VHA Enterprises, Inc., a healthcare/ financial services firm serving the capital needs of multi-hospital systems and other healthcare providers, and investment banking positions with Paine Webber, Inc. and L.F. Rothschild, Unterberg, Towbin, Inc. Mr. Cramer serves as board member (past president) of Big Brothers Big Sisters of Mercer County, NJ.

Mr. Cramer is currently Director of the Healthcare and Pharmaceutical Management Program and Adjunct Professor at Columbia Business School. He teaches three MBA courses: Strategy and Competition in Pharmaceuticals and Biotechnology, Healthcare Investment and Dealmaking, and Investing in Medical Technologies.

Gordon Carey '94
President
IMS Consulting Group

Gordon Carey has almost twenty years of consulting experience to pharmaceutical clients on commercial and business issues on five continents.  In particular, he has focused on developing payer strategies for pharma and biotech companies in the EU, US and in emerging markets.  His work includes strategies to engage KOLs, commercial and government payers, employers, patients and patient advocacy groups.

Gordon holds B.S. and M.S. degrees from the London School of Economics and Political Science, a Certificate in Education from Oxford University, and he graduated Beta Gamma Sigma from the Columbia Business School.  He is a regular speaker at industry conferences and has published in Drug Benefit Trends, Medical & Marketing Media and Pharmaceutical Executive on risk sharing and capitation.

Before joining Cambridge/IMS, Gordon was a Principal at Towers Perrin and an Associate Principal at McKinsey & Co.

 

Paul Clancy
Paul Clancy '87
EVP and CFO
Biogen Idec

Paul J. Clancy is the Executive Vice President and Chief Financial Officer at Biogen Idec and has served in these positions since August 2007. Mr. Clancy has also served as Senior Vice President of Finance and Vice President of Business Planning at Biogen Idec. Prior to the merger, Mr. Clancy had served as Vice President of Portfolio Management at Biogen Inc. since 2003. He joined the company in 2001 as Vice President, US Marketing. Before joining Biogen, Mr. Clancy spent 13 years at PepsiCo, serving in a range of financial and general management positions including most recently Vice President and General Manager of their Great West Business Unit. Mr. Clancy holds a Bachelor of Science degree in Finance from Babson College and a Master of Business Administration degree from Columbia Business School.

Geno Germano
President, Specialty Care and Oncology
Pfizer

Geno Germano is President and General Manager of the Specialty Care and Oncology Business Units for Pfizer Inc.

The Specialty Care Business Unit (SCBU) works closely with specialty physicians and stakeholders to provide medicines to help treat a variety of serious and life-threatening conditions. Specialty Care holds leadership positions in vaccines and in key disease areas such as inflammation, immunology, rare diseases, and vaccines. SCBU’s current portfolio includes more than 20 medicines in 12 disease areas, and a pipeline containing more than 25 compounds and indications in Phases II and III.

The Oncology Business Unit (OBU) is focused on improving the standard of care for cancer patients globally. With the full scale and scope of Pfizer support, the OBU has made rapid progress, with more than 20 molecules in development for various tumors including lung, breast, prostate, liver, kidney, colon and gastric diseases.

Germano also oversees the company’s Real World Data and Analytics platform to support and enhance the value of Pfizer’s inline and pipeline assets to patients; and improve customer decision-making based on comparative effectiveness, value-based purchasing and risk-sharing contracts.

Germano joined Pfizer from Wyeth, where he was President, U.S. and Pharmaceutical Business Units for Wyeth Pharmaceuticals, responsible for its U.S. based Pharmaceuticals, Biologics and Vaccines businesses. In addition, he led Global Strategy for the Pharmaceutical and Institutional business units for major products in Neuroscience, Gastroenterology, Women's Health, Infectious Diseases and Immunology.

In his more than 25 years in the pharmaceutical industry, Germano has held diverse positions, including Executive Vice President and General Manager for Wyeth Global Vaccines; Managing Director, Wyeth Australia and New Zealand; and Executive Vice President and General Manager of the Pharmaceutical Business Unit. He led numerous key product launches in primary and specialty care in gastroenterology, arthritis, infectious diseases, hemophilia, transplantation and oncology. Prior to joining Wyeth, Germano held leadership positions at several Johnson & Johnson companies.

Germano currently serves on the board of Zoetis (formerly a business unit of Pfizer), a global animal health company that discovers, develops, manufactures, and commercializes a diverse portfolio of animal health medicines and vaccines. He also serves on the Advisory Board of the Healthcare Businesswomen's Association, is a member of the Board of the Biotechnology Industry Organization and is a Trustee of the Albany College of Pharmacy, where he received his Bachelor of Science degree in Pharmacy in 1983.

Robyn Karnauskas, Ph. D.
Director, Biotechnology
Deutsche Bank

Robyn Karnauskas Ph.D. is Director, Biotechnology at Deutsche Bank. Robyn provides lead Equity Research coverage of the Biotechnology sector in North America. Robyn returned to Deutsche Bank in 2010 following a brief time at Morgan Stanley. Her return demonstrates Deutsche Bank's commitment to maintaining the firm's solid track record in providing fundamental and thoughtful research in the Biotech sector and throughout its broad Health Care platform. Prior to that, Robyn was Vice President and lead coverage Analyst on small and mid-cap biotech stocks at Deutsche Bank. She played an integral part in Deutsche Bank's #1 Institutional Investor ranked Biotech franchise and was named Institutional Investor's "Up and Comer" Biotech Analyst in 2009. Robyn originally joined Deutsche Bank from Bear Stearns in 2008. 

Robyn holds a Ph.D. in Cancer Biology from the University of Chicago and a B.S., in Biology from the Massachusetts Institute of Technology. Robyn resides in Manhattan with her husband & daughter. On her free time, Robyn enjoys seeing as much of the world as possible.